Elevated C-Reactive Protein and Subsequent Patient-Reported Cognitive Problems in Older Breast Cancer Survivors: The Thinking and Living With Cancer Study
Journal of Clinical Oncology · 10.01.2023 · 41 (2) · 295-306
DOI: 10.1200/jco.22.00406 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.01.2023. Verfasst von Judith E Carroll und 22 weiteren Autor:innen. Beteiligte Einrichtung: Cousins Center for Psychoneuroimmunology, University of California, Los Angeles, Los Angeles, CA. Hauptthemen laut MEDLINE: Cancer Survivors, Breast Neoplasms. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIA NIH HHS, NICHD NIH HHS.
Abstract (Originalsprache)
PURPOSE To examine longitudinal relationships between levels of C-reactive protein (CRP) and cognition in older breast cancer survivors and noncancer controls. METHODS English-speaking women age ≥ 60 years, newly diagnosed with primary breast cancer (stage 0-III), and frequency-matched controls were enrolled from September 2010 to March 2020; women with dementia, neurologic disorders, and other cancers were excluded. Assessments occurred presystemic therapy/enrollment and at annual visits up to 60 months. Cognition was measured using the Functional Assessment of Cancer Therapy-Cognitive Function and neuropsychological testing. Mixed linear effect models tested for survivor-control differences in natural log (ln)-transformed CRP at each visit. Random effect–lagged fluctuation models tested directional effects of ln-CRP on subsequent cognition. All models controlled for age, race, study site, cognitive reserve, obesity, and comorbidities; secondary analyses evaluated if depression or anxiety affected results. RESULTS There were 400 survivors and 329 controls with CRP specimens and follow-up data (average age of 67.7 years; range, 60-90 years). The majority of survivors had stage I (60.9%), estrogen receptor–positive (87.6%) tumors. Survivors had significantly higher adjusted mean ln-CRP than controls at baseline and 12-, 24-, and 60-month visits (all P < .05). Higher adjusted ln-CRP predicted lower participant-reported cognition on subsequent visits among survivors, but not controls ( P interaction = .008); effects were unchanged by depression or anxiety. Overall, survivors had adjusted Functional Assessment of Cancer Therapy-Cognitive Function scores that were 9.5 and 14.2 points lower than controls at CRP levels of 3.0 and 10.0 mg/L. Survivors had poorer neuropsychological test performance ( v controls), with significant interactions with CRP only for the Trails B test. CONCLUSION Longitudinal relationships between CRP and cognition in older breast cancer survivors suggest that chronic inflammation may play a role in development of cognitive problems. CRP testing could be clinically useful in survivorship care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Cousins Center for Psychoneuroimmunology, University of California, Los Angeles, Los Angeles, CA.
- Semel Institute for Neuroscience and Human Behavior, Department of Psychiatry & Biobehavioral Sciences, University of California, Los Angeles, Los Angeles, CA.
- Department of Psychiatry, University of North Carolina-Chapel Hill, Chapel Hill, NC.
- School of Aging Studies, University of South Florida, Tampa, FL.
- Department of Biostatistics, Bioinformatics, and Biomathematics, Georgetown University, Washington, DC.
- Lombardi Comprehensive Cancer Center, Department of Oncology, Georgetown University, Washington, DC.
ORCID-Profile: Judith E Carroll, Zev M Nakamura, Brent J Small, Xingtao Zhou, Tim A Ahles, Jaeil Ahn, Traci N Bethea, Martine Extermann, Deena Graham, Claudine Isaacs, Heather S L Jim, Brenna C McDonald, Sunita K Patel, Kelly Rentscher, Andrew J Saykin, Kathleen Van Dyk, Elizabeth C Breen, Jeanne S Mandelblatt
Förderung
- NCI NIH HHS
- NIA NIH HHS
- NICHD NIH HHS
Zitieren
APA
Carroll, J. E., Nakamura, Z. M., Small, B. J., Zhou, X., Cohen, H. J., Ahles, T. A., Ahn, J., Bethea, T. N., Extermann, M., Graham, D., Isaacs, C., Jim, H. S. L., Jacobsen, P. B., McDonald, B. C., Patel, S. K., Rentscher, K., Root, J., Saykin, A. J., Tometich, D. B., …, & Mandelblatt, J. S. (2023). Elevated C-Reactive Protein and Subsequent Patient-Reported Cognitive Problems in Older Breast Cancer Survivors: The Thinking and Living With Cancer Study. Journal of Clinical Oncology, 41(2), 295-306. https://doi.org/10.1200/jco.22.00406
Vancouver
Carroll JE, Nakamura ZM, Small BJ, Zhou X, Cohen HJ, Ahles TA, et al. Elevated C-Reactive Protein and Subsequent Patient-Reported Cognitive Problems in Older Breast Cancer Survivors: The Thinking and Living With Cancer Study. Journal of Clinical Oncology. 2023;41(2):295-306. doi:10.1200/jco.22.00406
BibTeX
@article{Carroll2023,
author = {Carroll, Judith E and Nakamura, Zev M and Small, Brent J and Zhou, Xingtao and Cohen, Harvey J and Ahles, Tim A and Ahn, Jaeil and Bethea, Traci N and Extermann, Martine and Graham, Deena and Isaacs, Claudine and Jim, Heather S L and Jacobsen, Paul B and McDonald, Brenna C and Patel, Sunita K and Rentscher, Kelly and Root, James and Saykin, Andrew J and Tometich, Danielle B and Van Dyk, Kathleen and Zhai, Wanting and Breen, Elizabeth C and Mandelblatt, Jeanne S},
title = {Elevated C-Reactive Protein and Subsequent Patient-Reported Cognitive Problems in Older Breast Cancer Survivors: The Thinking and Living With Cancer Study},
journal = {Journal of Clinical Oncology},
year = {2023},
volume = {41},
number = {2},
pages = {295--306},
doi = {10.1200/jco.22.00406}
}
EUVIMED